Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering

The additional sale brought aggregate offering gross proceeds to approximately $5,716,491 before fees and expenses.

Rhea-AI Summary

Cuprina Holdings (Cayman) (Nasdaq: CUPR) closed the sale of 648,373 additional Class A ordinary shares through its underwriter’s over-allotment option.

The option was exercised in full at $1.15 per share, generating approximately $745,629 in gross proceeds. Aggregate offering gross proceeds reached approximately $5,716,491, before underwriting discounts, commissions and estimated offering expenses. Cuprina intends to use net proceeds for new businesses, research and development, market expansion, brand awareness, equipment and infrastructure, and working capital. R. F. Lafferty acted as sole book-running manager.

2 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointOver-allotment exercise generated approximately $745,629 in gross proceeds for Cuprina. 5.5% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Cuprina plans to fund research and development and investment in equipment and infrastructure.

Negative

• Moderate pointIssuance of 648,373 additional Class A ordinary shares at $1.15 each dilutes existing holders.
• Minor pointOffering proceeds are subject to underwriting discounts, commissions and estimated offering expenses.

News Explained

Cuprina’s closed sale of 648,373 additional Class A shares increases the share count and reduces existing holders’ percentage ownership, absent offsetting changes.

Key Figures

Additional shares sold: 648,373 Class A ordinary shares Public offering price: $1.15 per share Additional gross proceeds: Approximately $745,629 +1 more

Additional shares sold

648,373 Class A ordinary shares

Full exercise of the underwriter’s over-allotment option

Public offering price

$1.15 per share

Additional shares sold in the over-allotment closing

Additional gross proceeds

Approximately $745,629

Before underwriting discounts and offering expenses

Aggregate gross proceeds

Approximately $5,716,491

Offering including the over-allotment closing, before deductions

Previous Offering Reports

2 past events · Latest: Sep 17

Same Type 2 events

1. Sep 17

   Offering closing

   24h Move

   +3.5%

   Initial offering closed at $1.15 per share; underwriter option remained available for 648,373 shares.

2. Sep 16

   Offering pricing

   24h Move

   -43.0%

   Offering priced 4,322,489 shares at $1.15, with a 648,373-share over-allotment option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

over-allotment option, form f-1

2 terms

over-allotment option financial

"full exercise of the underwriter’s over-allotment option"

An over-allotment option is a special agreement that allows underwriters to sell more shares than initially planned if demand is high. Think of it like a retailer offering extra units of a popular product to meet additional customer interest. This option helps ensure the full sale is completed and can also give investors extra shares if they want more.

form f-1 regulatory

"Registration Statement on Form F-1 previously filed"

A Form F-1 is the document a non-U.S. company files with U.S. regulators when it wants to sell stock or other securities to U.S. investors. It lays out the company’s business, finances, risks and how the offering will work, acting like a product manual and ingredient list so investors can judge what they’re buying. For investors, it’s a key source of verified information used to compare opportunities and assess potential reward and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it closed the sale of an additional 648,373 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriter’s over-allotment option granted in connection with the Company’s public offering (“PO”, together with such over-allotment closing, the “Offering”), at a public offering price of $1.15 per share, for a total of approximately $745,629 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses. As a result, the Company has raised aggregate gross proceeds of approximately $5,716,491, including the previously announced PO gross proceeds of approximately $4,970,862, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

The Company intends to use net proceeds from the Offering for expansion into new businesses, R&D activities to expand its product offerings, growth and expansion into new markets, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes.

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Ellenoff Grossman & Schole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.

The Offering is being conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-297299) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on September 15, 2026. The Offering is being made only by means of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. Copies of the final prospectus related to the Offering may be obtained, from R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. In addition, a copy of the final prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://www.cuprina.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the gross proceeds of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact

Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Cuprina raise through the underwriter’s over-allotment option?

Cuprina raised approximately $745,629 in gross proceeds through the full exercise of the option. It sold 648,373 additional Class A ordinary shares at $1.15 per share, bringing aggregate offering gross proceeds to approximately $5,716,491 before underwriting discounts, commissions and estimated offering expenses.